Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > A layman's thoughts on Roche and Adaptive Phase 3.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(236)
•••
Post by pelabooston Feb 04, 2024 3:22pm
423 Views
Post# 35862031

A layman's thoughts on Roche and Adaptive Phase 3.

A layman's thoughts on Roche and Adaptive Phase 3.I do not recall if we knew the PDAC Phase 3 was to be an Adaptive Phase 3. We have known for some time that the CPI was to be Tecentriq. Being an Adaptive Trial allows considerable flexibility (to allow for Cohort 5 of GOBLET and other changes), and the possibity of being a confirmatory trial.

We do not yet know how ONC/ONCY is going to fund this trial. I cannot see Roche stepping too far away from this, but until I have something material, I only know that Roche is supplying the CPI.

I would like to think that PanCAN is still involved in some capacity.

It does now seem  a safe bet that there will be a Phase 3 pancreatic cancer trial.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities